Title

Effects of Sertraline Treatment for Young Children with FXS

Authors

Laura Greiss Hess, MIND Institute, University of California, DavisFollow
Peter Mundy, MIND Institute, University of California, Davis
Randi Hagerman, MIND Institute, University of California, DavisFollow

Document Type

Conference Proceeding

Source

14th International Fragile X Conference

Location

Orange County, CA

Publication Date

7-2014

Department

Occupational Therapy

Abstract

Phenotypic manifestations for young children with fragile X syndrome (FXS) include: anxiety, sensory processing challenges, global language and communication deficits and intellectual and developmental disabilities. Many of these symptoms can be treated with medications, including selective serotonin reuptake inhibitors (SSRIs). However to date a clinical trial has not been conducted for children under five years old.

This study investigated the following question: Are there group differences on developmental outcome measures for those children treated with sertraline compared to placebo?

Comments

Presented at the 14th International Fragile X Conference, Orange County, CA

Recommended Citation

Hess, Laura Greiss; Mundy, Peter; and Hagerman, Randi, "Effects of Sertraline Treatment for Young Children with FXS" (2014). Collected Faculty and Staff Scholarship. 103.
https://scholar.dominican.edu/all-faculty/103